fig2
![Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma](https://image.oaes.cc/3c67cdb5-50a6-4a79-9974-ba1ce2bcbfac/4467.fig.2.jpg)
Figure 2. (A) Initial volume responses of 34 RMS models to cycle 1 of vincristine + actinomycin D + cyclophosphamide (VAC) using the SMT experimental design (ongoing expt.). (B) Kaplan-Meier plot for EFS of the same models. RMS: Rhabdomyosarcoma; VAC: vincristine/actinomycin-D/cyclophosphamide; EFS: event-free survival; SMT: single mouse testing.